NKTR
NASDAQ
$58.56
Nektar Therapeutics (NKTR)
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $153.25 (+161.70%)
Market Cap
$1.62B
PEG Ratio
0.31
Free Cash Flow Yield
-12.61%
Beta (5Y)
1.86
Price Chart
Valuation
Market Cap$1.62B
Forward P/E34.01
PEG0.31
P/S39.40
P/B3.80
Profitability
Total Revenue (TTM)$56M
Gross Profit (TTM)$56M
EBITDA-$120M
Profit Margin-284.2%
Operating Margin-352.2%
EPS-$9.07
Financial Health
Debt-to-Equity24.9%
Free Cash Flow Yield-12.61%
Growth & Risk
EPS 5Y CAGR-24.01%
Revenue 5Y CAGR-15.08%
FCF 5Y CAGR-8.70%
Beta (5Y)1.86
Sharpe Ratio1.48